Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | PDCD1 | Q15116 | 9/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13301313 | 0.97 | CA1 (0.51) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13301324 | 0.91 | CA9 (0.49) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13301330 | 0.89 | CA1 (0.53) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13301333 | 0.89 | CA1 (0.53) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13301311 | 0.89 | CA1 (0.53) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13301329 | 0.89 | CA1 (0.53) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13301310 | 0.88 | CA1 (0.55) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13301312 | 0.87 | PDCD1 (0.53) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13301317 | 0.84 | CA1 (0.54) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13301322 | 0.84 | CA1 (0.51) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | BALAGURUNATHAN KUBERAN | 2010-06-10 | — | — | US | disclosed |
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | BALAGURUNATHAN KUBERAN | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | CSGALNACT1, ST3GAL3, FUT6 | CA1 3096/4885CA2 3266/4885CA9 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.